Sanjivani Paranteral Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q2 FY26.
SP

Sanjivani Paranteral Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Sanjivani Paranteral Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹16Cr
−14.5% YoY
−13.4% QoQ
Net profit
₹2Cr
−28.7% YoY
−5.2% QoQ
Margin
14.52%
−1.2 pp YoY
−0.2 pp QoQ
Price₹193
Market cap₹235 Cr
P/E35.2

The short version

The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. The company expects a minimum of 10% sales growth for FY '26 compared to the previous year.

From Sanjivani Paranteral Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions.
  • Pune plant to start contributing commercially from Q3 FY '26, with full-year revenue potential of INR 90-110 crores.
  • Optimal capacity utilization of the Pune plant expected by Q2 FY '27, potentially contributing INR 20-25 crores quarterly.
  • Base business growth projected at 15-20% for the next year (FY '27), with total revenue expected around INR 150 crores.
  • Alevia Healthcare joint venture is forecasted to contribute INR 1-1.5 crores to the bottom line in FY '26 and expected to grow at least 100% in FY '27 (INR 3-3.5 crores+).

2 more points from Sanjivani Paranteral Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores.
  • The company is modernizing its facilities, incorporating AI to enhance efficiency and cost-effectiveness.
  • Development of import alternatives at the Pune plant is on track, with test licenses in place; products expected in the next 2-3 quarters.
  • The Pune plant has started commercial production recently and is expected to contribute INR 90-110 crores revenue on full-year operation, hitting optimal capacity by Q2 FY '27.

2 more points from Sanjivani Paranteral Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The Pune plant has a "very good healthy order book" in place, with commercial production started and business commencing from Q3 FY '26.
  • Orders for the Pune plant come from semi-government, government institutions, and exports to 3-4 established geographies.
  • Orders worth approximately INR 1 crore were held back due to local unrest in Nepal but have since been dispatched.
  • Order books are reported to be good, supporting improved sales in the next two quarters.

2 more points from Sanjivani Paranteral Ltd's call on order book

Create a free account to keep reading this call

Sanjivani Paranteral Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Sanjivani Paranteral Ltd Q2 FY26 results — key figures

Sanjivani Paranteral Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue1618-14.5%18-13.4%
Operating profit (EBITDA)23-21.1%3-14.8%
Operating margin14.52%15.72%-1.2 pp14.76%-0.2 pp
Profit before tax23-24.7%2-4.8%
Net profit (PAT)22-28.7%2-5.2%
EPS (₹)1.341.97-32%1.43-6.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sanjivani Paranteral Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sanjivani Paranteral Ltd Q2 FY26 results?

The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. The company expects a minimum of 10% sales growth for FY '26 compared to the previous year.

What is Sanjivani Paranteral Ltd share price analysis?

Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sanjivani Paranteral Ltd planning capital expenditure?

In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores.

Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.